Decision Resources Research Reports

Title	Published	Price
The Pricing and Reimbursement Environment for Immune Disease Therapies By: Decision Resources Introduction Drug therapies for immune disorders span an enormous price range—from a few cents per day to tens of thousands of dollars per year. Not surprisingly, payers impose restrictions on the use of the most \| more...	6/25/2009	$2,250.00
Special Report: 2009 Chartbook of International Pharmaceutical Prices By: Decision Resources Introduction Payers in all countries are increasing their pressure on manufacturers to cut prices. But prescription drug pricing and reimbursement policies vary markedly among the leading pharmaceutical markets, so, to best determine pricing, pharmaceutical companies \| more...	6/23/2009	$4,500.00
Opportunities in Menopausal Treatments: Will New Therapies Overtake Hormone Replacement? By: Decision Resources Introduction For decades, the efficacy of hormone replacement therapy (HRT) for some of menopause’s most troublesome symptoms eliminated any incentive to develop new approaches to treatment. However, data questioning the safety of estrogen-containing therapies have \| more...	6/20/2009	$2,250.00
Key Trends Fueling the Boom in Genetic Testing By: Decision Resources Introduction “Progress” aptly describes the expanding field of genetic testing. The field is more than finding linkages of genes with diseases: it encompasses technologies that have made it easier to quickly and more efficiently discover \| more...	6/15/2009	$2,250.00
SPECIAL REPORT: Understanding Treatment Dynamics and Needs in Juvenile Idiopathic Arthritis By: Decision Resources Introduction Although interviewed thought leaders acknowledge that available biological therapies have greatly improved treatment of juvenile idiopathic arthritis (JIA)—the most common rheumatic disease in children—they do not hesitate to point out unmet needs and remaining \| more...	6/12/2009	$4,500.00
New Strategies in Academic-Industry Collaborations By: Decision Resources Introduction Major pharmaceutical companies are showing increased interest in directly sponsoring academic research to access innovation and fill dwindling pipelines. Recent agreements involve higher levels of collaboration and funding, are broader in scope, and focus \| more...	6/11/2009	$2,250.00
Mega-Mergers: Executing Change in the Pharma Industry By: Decision Resources Introduction If consolidation is so advantageous for boosting a pharma company to a new level of productivity, why has Pfizer engaged in not just one but three mega-mergers in the past ten years: $92.3 billion \| more...	6/5/2009	$2,250.00
Biopharma Quarter: Key Trends and Events of the First Quarter of 2009 By: Decision Resources Introduction No Bear Stearns, no Lehman Brothers, no Chrysler, no humiliating hat-in-hand audiences with Congress. The biopharma industry has not seen one of its leaders tumble in the way that the financial and automotive industries \| more...	6/4/2009	$2,250.00
The Immune/Inflammatory Pipeline: A Strategic Review By: Decision Resources Introduction The current immune/inflammatory pipeline is over 375 drugs strong, with approximately 250 companies involved in these agents’ development. Yet, despite this robust pipeline size, Decision Resources analysts do not believe that any one agent \| more...	5/28/2009	$2,250.00
Dealmaking and Industry Outlook: Geriatric Diseases By: Decision Resources Introduction Rising Medicare costs driven by the aging baby boomers will, within the next few years, propel public national health expenditures in the United States above private national health expenditures for the first time ever. \| more...	5/21/2009	$2,250.00
SPECIAL REPORT: Riding the Biotech Economic Tsunami - Surfing to Safety or Wipeout? By: Decision Resources Introduction In 2008, the global financial crisis radically altered the dynamics of the biotech industry; many weaker companies will fail. However, private investment in biotech continued, and pharmaceutical companies invested significant sums in acquiring and \| more...	5/20/2009	$4,500.00
Dealmaking and Industry Outlook: Antivirals By: Decision Resources Introduction The infamous mutability of viruses has long challenged antiviral drug developers, but complete genome sequences are now known for thousands of viruses, and the viral proteins encoded in these sequences are being used as \| more...	5/7/2009	$2,250.00
Immune/Inflammatory Disease: Early-Stage R&D Technologies and Dealmaking By: Decision Resources Introduction Today’s leading autoimmune/inflammatory disease drugs are blockbusters, but what are the remaining unmet needs and next opportunities? Dealmaking patterns indicate that Big Pharma continues to look to small technology companies to tap opportunities \| more...	5/6/2009	$2,250.00
Strategic Overview of Spondyloarthropathies: Tapping the Market Opportunity of Niche Immune Diseases By: Decision Resources Introduction A trio of niche immune diseases have gained drug developers’ attention after a period of strong sales growth. Treatment of these diseases, the spondyloarthropathies (SpAs), was revolutionized by the availability of TNF-alpha inhibitors and \| more...	4/30/2009	$14,500.00
Market Access, Pricing, and Reimbursement News in the First Quarter of 2009 By: Decision Resources Introduction The fourth quarter of 2009 was characterized by a wide range of new pricing and reimbursement initiatives in the United States but more focused measures in most of the world’s other leading pharmaceutical markets. \| more...	4/30/2009	$2,250.00
The Cardiovascular Disease Pipeline: A Strategic Review By: Decision Resources Introduction The robust and diverse cardiovascular disease (CVD) R&D pipeline is evidence of companies’awareness that these diseases remain leading causes of death worldwide, and that the chronic nature of many CVDs offers significant commercial opportunity. \| more...	4/27/2009	$2,250.00
Nucleic Acid Testing: A Vehicle for Advancing Personalized Medicine By: Decision Resources Introduction One of the fastest-growing segments of molecular diagnostics is nucleic acid testing (NAT). NAT is central to the life sciences industry, to improved healthcare, and to personalized medicine. Tools based on NAT are used \| more...	4/17/2009	$2,250.00
Dealmaking and Industry Outlook: Therapeutic Antibodies and Vaccines for Cancer By: Decision Resources Introduction Targeted cancer therapies have achieved phenomenal growth, and many MAb-based immunotherapies are blockbusters or mega-blockbusters. This market success is due not only to these MAbs’ ability to treat unmet need in many cancers but \| more...	4/9/2009	$2,250.00
Formulary Decision Making in the United States By: Decision Resources Introduction The U.S. pharmaceutical industry is facing the worst combination of pressures in memory—the most severe recession in decades, a dramatic slowdown in pharmaceutical sales, a new U.S. administration intent on slashing healthcare costs, and \| more...	3/31/2009	$2,250.00
Insights into Platform Technology and Early-Stage Pipeline Mergers and Acquisitions By: Decision Resources Introduction The continuing activity in mergers and acquisitions (M&As) involving biotechnology companies refl ects the industry’s growth and maturity. Biotech companies are increasingly merging for strategic reasons that include business, clinical, and technological considerations. In \| more...	3/30/2009	$2,250.00
Drug Benefit Trends in the United States By: Decision Resources Introduction After many years of vigorous growth, the world’s dominant pharmaceutical market faces unprecedented challenges in the near future. This report, which features 27 fi gures and tables, analyzes recent drug benefi t trends and \| more...	3/30/2009	$2,250.00
Know the Other "Omics": Exploring Drug and Diagnostics Development Through Proteomics By: Decision Resources Introduction Genomics has paved the way for its cousin, proteomics, to secure its share of the “omics” hype. Researchers look to proteomics to deliver on the promise to assess the viability of drug targets for \| more...	3/30/2009	$2,250.00
Biopharma Quarter: Key Trends and Events of the Fourth Quarter of 2008 By: Decision Resources Introduction 2008 came to a close amid political transition in the world’s largest pharmaceutical market and economic upheaval in all of the world’s markets. Our review of key events that occurred in the fourth quarter \| more...	3/30/2009	$2,250.00
Will Emerging Agents Disrupt the Psoriatic Arthritis Market? By: Decision Resources Introduction Surveyed rheumatologists are open to prescribing emerging agents for psoriatic arthritis (PsA) patients upon approval. That is good news for the PsA patients who fail to respond to TNF-á inhibitors; treatment options are limited \| more...	3/27/2009	$2,250.00
Dealmaking and Business Strategies in the Age of Personalized Medicine By: Decision Resources Introduction The promise of personalized medicine is having a profound impact on the healthcare industry. It promises to change the way healthcare is delivered and how drugs and diagnostics are developed. Pharma companies are still \| more...	3/26/2009	$2,250.00
Title	Published	Price

< prev 1 2 3 4 5 6 7 8 9 10 next >

Phone: 800.298.5699 (US) or +1.240.747.3093 (Int'l)
Hours: 7:00 a.m. to 7:00 p.m. EST Monday through Friday
Email: customerservice@marketresearch.com
Copyright © 1999-2009, All Rights Reserved, MarketResearch.com
11/22/2009 - 4